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Paper
Abstract
Phenotypes have gained increased notoriety in the clinical and biological domain owing to their application in numerous
areas such as the discovery of disease genes and drug targets, phylogenetics and pharmacogenomics. Phenotypes, defined
as observable characteristics of organisms, can be seen as one of the bridges that lead to a translation of experimental find-
ings into clinical applications and thereby support ‘bench to bedside’ efforts. However, to build this translational bridge, a
common and universal understanding of phenotypes is required that goes beyond domain-specific definitions. To achieve
this ambitious goal, a digital revolution is ongoing that enables the encoding of data in computer-readable formats and the
data storage in specialized repositories, ready for integration, enabling translational research. While phenome research is
an ongoing endeavor, the true potential hidden in the currently available data still needs to be unlocked, offering exciting
opportunities for the forthcoming years. Here, we provide insights into the state-of-the-art in digital phenotyping, by means
of representing, acquiring and analyzing phenotype data. In addition, we provide visions of this field for future research
work that could enable better applications of phenotype data.
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Introduction
Phenotypes are broadly defined as observable characteristics of
organisms and have gained great importance since the discov-
ery of the causative relationship between a given underlying
genetic mechanism (e.g. gene expression levels, mutations) and
its phenotypic manifestation. Subsequently, diverse initiatives
have focused on developing and curating resources that capture
this causal relationship at multiple levels and in the context of
multiple organisms. Examples include, but are not limited to
the Online Mendelian Inheritance in Man (OMIM) database [1],
the Mouse Genome Informatics database (MGD) [2], FlyBase [3]
and the Zebrafish Model Organism database (ZFIN) [4].
The increasing development and exploitation of phenotypes
has led to a varied range of applications: identifying disease
genes [5–9] and characterizing functionally yet unclassified
genes [10–12], repurposing drugs [13, 14], pharmacogenomics
[15–17] and pharmacovigilance [18], as well as solving evolu-
tionary questions [19, 20].
The goal of this review is to synthesize the state-of-the-art
in the past 10 years of Phenome Research, and hence provide a
unique and broad access point for those interested in studying
topics in specific areas of phenomics. The areas covered include
both phenotype data evolving from biological experiments and
data needed in a clinical environment. This work also presents
visions for the coming years in phenomics research, as it de-
rives a series of open challenges, based on input collected from
the community. We note here that the work addressed in this
article focuses on computational phenotyping, i.e. the collec-
tion, representation and processing of phenotypes in a com-
puter-interpretable format.
To enable a structured navigation of the field, we map the
content of the review onto the four conceptual dimensions of
phenomics, considered from a computational perspective (de-
picted in Figure 1): representation, interoperability, acquisition
and processing. These four dimensions have been identified
and described in an earlier review [21] and are used for simpli-
city here. Representation focuses on semantic modeling and as-
pects of knowledge capturing. Interoperability, an orthogonal
dimension to representation, aims to facilitate intra- and
interspecies phenotype mappings. Acquisition refers to the
transformation of the raw data into semi-structured or struc-
tured phenotype representations. Processing (or application)
uses externalized phenotypes to address fundamental or spe-
cific challenges, from variant prioritization and diagnosis to
individualized preventive care or drug repurposing.
Each of these dimensions encapsulates a multitude of as-
pects that reflect in their aggregated form the intrinsic complex-
ity of phenotypes. For example, subject to the underlying
domain, the granularity of the representation of phenotypes
may differ depending on their application. While biologists cap-
ture data that may be too detailed for clinical applications, clin-
icians need solid and thoroughly supported evidence to be able
to test hypotheses derived from biological experiments.
Furthermore, phenotypes may be defined and represented in
the context of different organisms, e.g. decreased bone mineral
density (MP:0000063) in the Mammalian Phenotype Ontology
(MP) [22] and Osteopenia (HP:0000938) in the Human Phenotype
Ontology (HPO) [23], even though they may share an underlying
goal from a translational perspective, such as the documenta-
tion of a certain gene function. This leads to the need for
achieving cross-species interoperability to enable integrated
processing. Finally, the phenotype acquisition process poses its
own challenges, i.e. technical (process automation or interface
usability), social (incentive) and ethical (privacy). In the follow-
ing we discuss in depth each of the dimensions introduced
above. A summary of all the resources provided in this manu-
script is provided in Table 1.
State-of-the-art phenome research
Representation
A phenotype can be any observation of a normal or abnormal
state of an anatomical, physiological or biochemical property of
an organism. While phenotypes in a biological domain are re-
corded as results from biological experiments, phenotypes in a
clinical domain are used to report the assessment of patients.
Phenotypes span from the molecular level to the organism level
[42]. To enable the other three dimensions to reach their full po-
tential, a representation is needed that is well understood by
humans, and at the same time, computer-readable and hence
amenable to computational analyses. Such a representation
does not only have to cover normal and abnormal phenotypes
within a species, but also has to facilitate the bridging across
species and enable integration of heterogeneous data at differ-
ent levels of granularity.
From a computational perspective, phenotypes take diverse
representations: (i) free-text descriptions—e.g. as part of the
OMIM disease presentations, (ii) vocabularies—e.g. the clinical
synopsis in OMIM, or the London Dysmorphology Database ter-
minology [25], and (iii) ontologies—i.e. vocabularies augmented
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with domain-specific relationships—e.g. HPO or MP. While free
text descriptions support a better human understanding, they
limit the possibilities for automated data analysis [43]. With the
abundance and ever-increasing amount of data, the ultimate
goal is to build a uniform and consistent computer-readable
representation, one that enables a seamless collection and inte-
gration of phenotypes recorded in biological studies, as well as
in a clinical environment. Ideally, this uniform, global represen-
tation would also account for both qualified and quantified data
and enable flexible conversion where possible. In cases where
conversion is not possible, this universal representation would
have to be extended with mappings.
Ontologies to represent phenotypes
Currently, the field consists of a varied set of vocabularies and
ontologies that support, in various forms, the abovementioned
goal. In particular, driven by the wide adoption from the bio-
medical community, ontologies have become the de facto
standard for representing phenotypes. To achieve the goal to its
full extent, the community has followed two complementary
approaches for modeling and integrating phenotype data: a pre-
composed and a post-composed representation (see Figure 2).
The pre-composed approach treats each phenotype as an
atomic entity, using individual expressions most suitable to
general human understanding. For example, an ontology
Figure 1. The four dimensions of the phenotype development phases. Representation: Subject to the underlying domain and goal, phenotypes may be represented at
different granularity levels. Interoperability: Existing ontologies and vocabularies externalize domain-specific phenotype knowledge at different levels of granularity.
Acquisition: Capturing and documenting phenotypes in any representational format can be achieved manually (via curation) or automatically (via text mining).
Processing: Representing and capturing phenotypes in a structured manner (a form that also enables interoperability) has led to their application in a large variety of
domains. The arrows denote direct points of connection between the several phenotyping dimensions. Note that this figure only serves as illustration of the interplay
of the four dimension and, thus, is not aimed at comprehensiveness (e.g. interoperability could also be achieved with a mapping instead of EQ statements).
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adopting this representation consists of concept definitions like
‘erythrocytopenia’ or ‘deficiency of red blood cells’ / ‘deficiency
of erythrocytes’. These concepts are easily understood by
humans and also facilitate computational analysis.
The post-composed representation uses elementary pheno-
typic units from existing ontologies to compose specific com-
plex phenotypes. One mechanism to postcompose phenotypes
is the entity-quality (EQ) statement approach [24, 44]. For ex-
ample, instead of defining ‘erythrocytopenia’ as an atomic con-
cept, this approach represents the meaning of the phenotype by
linking the quality ‘deficiency’ with the anatomic entity ‘red
blood cells’. This link is then captured via a logical axiom using
concepts introduced by existing ontologies, such as the Gene
Ontology (GO) [26] and the Phenotypic quality and Trait
Ontology (PATO) [24]. The caveats of the postcomposition result
from the development overheads in building post-composed
statements. Additionally, a number of pre-composed phenotype
ontologies still need to be transformed into a post-composed
representation.
‘Normal’ and ‘abnormal’ phenotypes
Some of the existing phenotype representations focus on devi-
ations of phenotypes (i.e. their status or quality, from a
reference phenotype) [27]. The reference phenotype in the case
of model organisms could be either the wild type of the organ-
ism or a specific strain from which the mutation has been gen-
erated. In the best case, the phenotype representations form
the core that enables interoperability of different data reposito-
ries, possibly covering different organisms and being collected
with different aims in mind. The quality of the phenotypic re-
source, i.e. the consistency of the phenotypic definitions, the
overall structure of the phenotype semantic resource and in
particular the completeness of the electronic resource, holds
the key to enabling efficient data analysis, interpretation and
decision support.
To extend beyond representing ‘abnormal’, Shimoyama et al.
have extended the representation of phenotypes to also incorp-
orate environmental factors as well as methods used to meas-
ure the phenotype [45]. The developed ontologies have been
used to annotate both rat (http://rgd.mcw.edu/wg/physiology)
and human data (http://cover.wustl.edu/Cover/). Furthermore,
the suggested framework allows for the annotation of quanti-
fied phenotypes (e.g. ‘blood sugar levels> 8.5 mmol/L’) instead
of ‘abnormal / increased blood sugar levels’. While this way of
representation could be used to represent the reference pheno-
type, a data curator is needed to provide this information.
Table 1. Summarizes all resources mentioned throughout the manuscript, together with their URL and reference (where applicable)
Resource Link Reference
Online Mendelian Inheritance in
Man database
http://omim.org/ [1]
Mouse Genome Database http://informatics.jax.org/ [2]
FlyBase http://flybase.org/ [3]
Zebrafish Model Organism Database http://zfin.org/ [4]
Mammalian Phenotype Ontology http://www.berkeleybop.org/ontologies/mp/ [20]
Human Phenotype Ontology http://purl.obolibrary.org/obo/hp.obo [21]
London Dysmorphology Database http://www.lmdatabases.com/ [23]
Gene Ontology http://geneontology.org/ [24]
Phenotypic quality and Trait Ontology http://purl.obolibrary.org/obo/pato [25]
OrphaNet http://www.orpha.net/consor/cgibin/index.php [26]
PharmGKB https://www.pharmgkb.org/ [27]
Zebrafish Anatomical Ontology http://purl.obolibrary.org/obo/zfa [28]
International Mouse Phenotyping
Consortium
http://www.mousephenotype.org/ [29, 30]
IMPReSS https://www.mousephenotype.org/impress
Phenote http://www.phenote.org/
PhenoTips https://phenotips.org/ [31]
MetaMap http://www.nlm.nih.gov/research/umls/implementation_resources/metamap.html [32]
NCBO Annotator https://bioportal.bioontology.org/annotator
cTakes http://ctakes.apache.org/ [33]
ShARE/CLEF 2013 https://sites.google.com/site/shareclefehealth/data [34]
DeepPhe http://cancer.healthnlp.org/
Bio-LarK http://bio-lark.org/ [35]
PhenoMiner https://sites.google.com/site/nhcollier/projects/PhenoMiner [36]
Unified Medical Language System http://www.nlm.nih.gov/research/umls/ [37]
Unified Medical Language System
Metathesaurus tool
http://www.nlm.nih.gov/pubs/factsheets/umlsmeta.html [38]
UberPheno http://purl.obolibrary.org/obo/hp/uberpheno/ [39]
SNOMED CT http://www.nlm.nih.gov/research/umls/Snomed/snomed_main.html [40]
AgreementMaker http://agreementmaker.org/ [41]
Zooma http://www.ebi.ac.uk/fgpt/zooma/
SIDER http://sideeffects.embl.de/ [14]
AVAToL http://avatol.org/ [17]
PhenoScape http://phenoscape.org/ [18]
ORCID http://orcid.org/
ResearcherID http://www.researcherid.com
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Conversions from the different states of ‘normal’, e.g. similar
tests in different species, are not automatically available.
Representing qualitative and quantitative phenotypes
Other desiderata for phenotype representations are focused on
the exploitation of ontologies for efficient propagation of experi-
mental findings in basic phenomics research into the clinical
domain and improved research efficiency in both domains
(translational medicine). Consequently, phenotype descriptions
have to meet clinical needs and cover those diseases that are
most relevant to the clinical context. Experimental phenotypic
descriptions are detailed and reflect the experimental setup,
whereas clinical descriptions suffer from time constraints and
thus tend to lack observational detail. Furthermore, experimen-
tal and clinical phenotypic descriptions may be organized at di-
verse levels of granularity and may be biased toward a specific
perspective. For example, experimental findings provide the op-
portunity to capture and represent quantitative traits (e.g.
‘blood sugar> 8.5 mmol/L’), which may require adaptation into
qualitative terms (‘high blood sugar’) for clinical purposes.
Similarly, from a diagnosis perspective, one may require a com-
plete and individualized view over the phenotypic profile,
which may include degrees of severity [28] and longitudinal
phenotypes [29], hence adding to the overall complexity of the
representation.
Representation of phenotypes: summary
The resources for representing phenotypes have reached a
point where they are able to provide a solid and rich foundation
for building advanced acquisition and processing mechanisms.
Open challenges still exist, e.g. modeling degrees of severity,
normal states or negation (i.e. explicitly mentioning the absence
of an abnormality) or mapping quantitative traits to qualitative
concepts to provide deep knowledge capturing methodologies.
Acquisition
Acquisition involves the collection and storage of phenotype in-
formation from various resources (see Figure 3), such as OMIM
or OrphaNet, a rare disease database [30]. While some of these
resources are mainly built through manual curation, e.g. MGD,
others rely already on (semi-)automated preprocessing to en-
hance curator throughput. For example, PharmGKB [46] uses an
automated classification system to determine relevant publica-
tions and extract gene–drug relationships that are then pro-
vided to curators for verification [31, 47].
Manual acquisition of phenotypes
Manual acquisition of phenotypes can be done either by cur-
ation of the literature or by direct submission from investiga-
tors. These two main modes are used to annotate model
organism data with phenotype observations and their concep-
tual descriptions. In the case of MGD, curators provide standard
Figure 2. To date, phenotypes have mostly been captured and defined using a pre-composed and/or a post-composed representation. A pre-composed representation
assumes the definition of a phenotype as a monolithic concept—a concept that captures the essence of the phenotype semantics. The post-composed representation
decomposes the phenotype into an Entity–Quality pair, with its individual components being mapped to appropriate ontological concepts. In this case, the phenotype
semantics is denoted by the compositional property of the pair. The transition between pre-composed and post-composed is realized via logical axioms. Both forms of
representation have been successfully applied across different species.
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phenotype descriptions from MP along with supporting evidence.
ZFIN similarly provides phenotypic data with evidence coming
from manual curation and individual investigator contributions
using the Phenote software (http://www.phenote.org/). Phenote
allows description of phenotypes in an EQ format, which makes
use of any ontology in the Open Biological and Biomedical
Ontologies [48] format, including PATO, the Zebrafish Anatomical
Ontology [32] and GO.
The International Mouse Phenotyping Consortium (IMPC)
[33, 49] has applied phenotype encoding standards [50] through
a set of standard operating procedures (SOPs; as defined in
IMPReSS: https://www.mousephenotype.org/impress) for re-
cording high-throughput phenotype measurements in the lab.
Each of the SOPs describes not only the experimental setup for
the measurement of the required parameters, but also the
ontology annotation this test may induce. For example, the SOP
designed to assess the grip strength of a mouse includes the
suggestion of the MP term ‘abnormal grip strength’
(MP:0001515).
In addition to Phenote mentioned above, one example of a
system that was designed specifically for phenotype capture in
a manual mode is PhenoTips [51]. This open-source system as-
sists clinicians to record phenotypic profiles for patients with
rare genetic disorders using HP and OMIM, potentially allowing
for diagnosis and comparative phenotype analysis.
Discovering evidence for the causes of human disorders and
providing treatment are common goals across the clinical and
scientific communities. However, the understanding of pheno-
types has traditionally been different between the two com-
munities. Clinicians generally consider phenotypes to be
aberrations, i.e. deviations from normal morphology, physi-
ology or behavior [52], while scientists working on biological ex-
periments, such as mutation experiments, have adopted a more
pragmatic definition of a selective profile of all the observable
characteristics of an organism. This division stems in part from
a focus on the overt expression of the syndromes themselves
[53] on the one hand and on the pathway from syndrome to
gene expression on the other. Both are crucial to understanding
the complex nature of disorders, as Sabb et al. point out [53].
This difference is reflected in the type of data that each commu-
nity creates and the systems that have been built to support
data capture by each.
Semi-automated and automated phenotype acquisition
With the increasing amount of data that is published on a day-
to-day basis, manual approaches for data curation become
more and more time-demanding and costly, so that computer
assistance in screening (document retrieval) and preparing data
(information extraction) is unavoidable. The degree to which
computer assistance is enabled determines whether the
method is semi-automated or automated. While in a semi-
automated setting a curator manually verifies the extracted
data, in an automated setting no manual input is required.
However, given the absence of manual verification and the cur-
rent state-of-the-art in text processing, the data generated with
an automated method may contain some incorrect data.
The structural and semantic complexity of phenotype terms,
coupled with the scale and changing nature of literature-based
phenotype descriptions, makes a traditional fully manual ac-
quisition approach difficult to sustain, leading to potential du-
plication, inconsistency and sub-optimal coverage. This has
created a growing interest in text/data mining techniques. A di-
verse and growing research community is evolving that aims to
exploit biomedical natural language processing for the extrac-
tion of structured data from free-text and its annotation with
the semantic resources that already exist. Although not specif-
ically aimed at phenotypes, knowledge brokering tools such as
MetaMap [34], the NCBO Annotator and the Apache cTAKES [54]
have all been widely used for concept annotation of text to bio-
medical ontologies and could be used to yield these building
blocks. The issue of customizing these generic tools to the
Figure 3. The increasing amount of data made available over the course of the past years have rendered manual phenotype curation impractical. While automating
the process is in principle the only viable solution, it possesses its own plethora of technical challenges. These include, among others: (i) boundary detection, i.e. iden-
tifying the exact span of text that represents a phenotype candidate; (ii) disambiguation and alignment, subject to the desired level of granularity and the underlying
knowledge source; and (iii) interpretation, which covers lack of context, hedging or negation.
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extraction of phenotypes in specific disease domains is a key
challenge.
Extraction of structured information from electronic health
records (EHRs) has a long history of research, e.g. [35, 36, 38, 55].
Progress has been hampered by the balance that needs to be
drawn between respecting patient privacy and the need for data
to develop comparable gold standards. In the past few years,
several initiatives have led the way in making available anony-
mized collections of EHRs, e.g. Informatics for Integrating
Biology and the Bedside (i2b2) [56] and recently ShARE/CLEF
2013 [57]. These tasks aim to identify entities of clinical interest
including medical problems, tests and treatments. While nei-
ther of these data sets explicitly annotates phenotypes, these
entities are highly relevant to phenotype acquisition. Fu et al.
suggested an annotation scheme to capture phenotypes for
chronic obstructive pulmonary disease in EHRs, which has been
implemented in Argo [58] to annotate a corpus of 1000 clinical
records [59]. Furthermore, the newly launched DeepPhe project
(http://cancer.healthnlp.org/) focusses on phenotypes relevant
in the cancer genomics domain.
Using the scientific literature as a source, several groups
have been active in developing approaches explicitly for pheno-
types. These include the Bio-LarK system, which has been
applied to skeletal dysplasia [39] and the PhenoMiner system,
which has been applied to the cardiovascular and autoimmune
systems [60]. Work by Khordad et al. [37] has looked at a more
mixed domain using the Unified Medical Language System
(UMLS) Metathesaurus tool [40]. Ongoing challenges in process-
ing EHRs are: descriptive naming (e.g. typical course face, het-
erogeneous ECG abnormalities), disjoint phenotype mentions
(e.g. blood pressure was observed to be elevated) and coordi-
nated terms (e.g. slow healing and excessive scarring).
Harmonization to existing ontologies presents an additional
layer of challenge in deciding how to align phenotype mentions
that are more or less specific than extant concepts and how to
provide sufficient evidence for human curators.
While automated methods are not as thorough as curators,
they overcome some of the bottlenecks experienced with man-
ual curation, e.g. high time consumption and low throughput.
In general, there is a trade-off between thoroughness (precision)
and the amount of acquired data (recall) returned as results
from these methods, i.e. automated methods may not return all
relevant results and may return some incorrect results.
Acquisition of phenotypes: summary
The acquisition and harmonization of phenotypes is an ongoing
challenge to be met using evidence from a variety of sources
(e.g. EHRs, scientific literature, clinical reports). The key issue
for automated approaches involving natural language process-
ing support is to identify and resolve lexical, syntactic and se-
mantic heterogeneity.
Interoperability
The interoperability dimension of phenomics research focuses
on making all the available phenotype data integrable with
other data sources, e.g. diseases or results from genome ana-
lyses. The overarching goal of interoperability is to facilitate
translational research and biological discoveries [21]. Current
and past work falling into this dimension can be summarized as
standardization efforts, alignment of phenotypes within and
across species and mapping to other resources. Challenges arise
from the many levels of complexity phenotypes can span [42] as
well as the development of multiple, and mostly disparate, re-
porting schemes [22, 23, 41].
Interoperability through semantic layers
A prerequisite for interoperable phenotype resources is a se-
mantic layer that spans across the resources applied and allows
to keep the consistency and specificity contained in each of the
resources. For example, despite standardization efforts such as
the Minimal Information for Mouse Phenotyping Procedures
[61], the existing landscape of mouse phenotype resources is
not fully interoperable and hard to manage [62]. A similar scen-
ario is seen in hospitals where different wards use disparate
ways of describing a patient. As a consequence, the data for a
patient cannot readily be used for further analysis, preventing
potential holistic treatment opportunities. However, the need
for standardized reporting has been recognized and is imple-
mented through SOPs in the IMPC [33, 49, 50].
While historically there have been different phenotype rep-
resentations for different species, such as the human, mamma-
lian, fly and worm phenotype ontology (see 2.1 representation),
EQ statements (see Figure 2) have been suggested to integrate
phenotypes across different species [24, 44]. In addition, an
amendment to the existing EQ statements was suggested to
make them interoperable with anatomy and physiology ontolo-
gies [63] to extend the links across the different layers of com-
plexity. To make the annotation for three different species
(human, mouse and zebrafish) more accessible, Ko¨hler and au-
thors made the UberPheno ontology publicly available [64].
Interoperability achieved through mappings (alignment)
Further to the representation of phenotypes with EQ state-
ments, manual [65] and automated methods are in progress to
align different pre-composed semantic representations. One ex-
ample is UMLS [66] that combines over 180 vocabularies, termi-
nologies and ontologies, such as SNOMED CT [67]. The
integration of new resources into UMLS is semi-automated.
Conflicts between concepts from newly added resources and
concepts already in UMLS are manually resolved to ensure a
high-quality alignment of all the incorporated terminologies,
vocabularies and ontologies.
As an alternative to manual and semi-automated solutions,
tools exist that provide fully automated alignments between
ontologies, such as AgreementMaker [68] and Zooma (http://
www.ebi.ac.uk/fgpt/zooma/). While AgreementMaker takes lex-
ical matching and ontological features into account, Zooma
uses phonetic matching algorithms for the alignment. In many
cases, the resulting alignments often associate one term with
multiple concepts (1:n mapping). Bottlenecks in the automated
alignment are caused by species-specific jargon [69, 70] and by
phenotypes that only exist in one of the species and not the
other.
In addition to the alignment of multiple resources, mappings
are required that would facilitate the integration of diverse re-
sources spanning across the different layers of complexity of an
organism. While phenotypes in model organisms have been as-
signed to genes as well as to specific models (determined by al-
lele and background in addition to gene, e.g. MGD), in human,
mostly inheritable diseases have been annotated. However, if
we were to follow the pathway from the modified gene to the
observed phenotypes, a mapping between pathways and
phenotypes would also be required [71]. As mentioned above,
some integration with other resources has been achieved, e.g.
with anatomy and physiology ontologies, but a much larger
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coverage is required to unlock the full potential of knowledge
discovery using phenotype data.
Interoperability of phenotypes: summary
The need for unified and integrable representation of pheno-
types has been recognized, and projects are underway to im-
prove the current situation. However, there is still a huge
amount of legacy data that need to be dealt with.
Processing
Processing (or application) is concerned with the use of pheno-
type data that have either been reported in structured form or
extracted with, for example, text mining methods (see acquisi-
tion methods of phenotypes). Subject to the target domain, the
usage of phenotype data can be classified into four broad cate-
gories: (i) clinical research (diagnosis, prognosis, patient match-
making, variant prioritization, personalized medicine, drug side
effects); (ii) study of genome–phenome interactions to advance
the understanding of disease causation or achieve personalized
therapies; (iii) cross-resource consistency analysis; and (iv) evo-
lutionary research. It is worth noting that in most cases pheno-
type data have been used in a cross-species context, hence
transforming the interoperability dimension into a first-class
citizen, rather than an application scenario.
Application of phenotypes to study the origins and pathology of
diseases
The application area of clinical research consists of a varied set
of specific goals, which represent in practice coherent research
streams on their own. Phenotypes have been used as unique
source of data, for example, for disease prediction [72, 73], min-
ing key disease characteristics or characteristic phenotypes [16,
17, 74] or patient match-making [51]. Furthermore, phenotypes
have been used to support the understanding of the genetic
mechanism of diseases via direct association with genotype
data [5, 9, 12], as a mapping bridge across species data [7, 8] and
in conjunction with the entire set of OMICS data [75] or to im-
prove variant prioritization for accurate diagnosis [76, 77].
More recently, phenotypes have played a major role as a dis-
covery agent in large-scale genome-wide association studies [78–
80]. In particular, projects such as the 100 000 Genomes Project
(http://www.genomicsengland.co.uk/the-100000-genomes-project/)
as well as the eMerge Network (https://emerge.mc.vanderbilt.edu/
?page id¼58) aim to support the area of Pharmacogenetics by
linking data from EHRs to sequence information from patients
to improve diagnosis and treatment. Similarly, Phenome-wide
Association Studies (PheWAS) [81–83] allow for the identification
of genes that possibly implicate a disease and can provide prov-
enance for results determined through Genome-wide associ-
ation studies.
Phenotypes and ethnicity
Generic phenotypes have an immense potential, which has
been only recently discovered and exploited. For example, eth-
nic differences have been shown to explain the optimal states
of the human blood glucose levels—expressed via the relation-
ship between insulin sensitivity and insulin response [84].
Similarly, when used in the context of a shared genetic architec-
ture, such data validated the existence of statistically significant
relationships between the platelet count and alcohol depend-
ence, or between the alkaline phosphatase level and venous
thromboembolism [85]. This application area is characterized
by a specific set of challenges, emerging from the novel
combination of numeric data (from tests and measurement),
abnormalities and standard traits. One important and still un-
solved problem in the processing of phenotypes is the lack of
alignment between measurement representations and pheno-
typic abnormalities, as well as the ability of representing states
of normality and longitudinal phenotypic data resulting from
tests and measurements.
Phenotypes in drug repurposing
Phenotypes expose the effects of drug treatments, and hence,
enable the study of their general effects, the relation between
dosage and effects, as well as the interaction between drugs.
Existing literature on this topic maps perfectly onto these three
aspects. Phenotypes, as adverse drug reactions, have been mod-
eled and captured, as early as 2010, by the SIDER initiative [14]
and have been used to investigate the causal relationship be-
tween dosage and effect by [15]. In an exercise that combines
large-scale acquisition and processing, LePendu et al. have used
phenotypes as indicators of adverse drug reactions, as well as
signals of adverse events associated with drug–drug inter-
actions [18]. Finally, with the increasing curation, adoption and
use of cross-species phenotype data, it has been shown that an
effective mapping between model organisms and drug effect
profiles based on similarity can be applied to successfully sug-
gest candidate drug targets [13].
Phenotypes in evolutionary studies
In this context, phenotypes have been used to understand pat-
terns of diversification and to gain additional knowledge on
trait evolution. Two particular initiatives have focused on this
aspect. The AVAToL project [19] represents a collaborative and
multidisciplinary effort that combines text mining, image ana-
lysis and the wisdom of the crowds to discover and document
species phenotypes. Their ultimate goal is to advance phylogen-
etics research and to enable a faster and more accurate con-
struction of the Tree of Life. The Phenoscape knowledge base
[20], on the other hand, integrates phenotype data acquired on
over 2500 teleost fishes with structured phenotype data from
zebrafish genes to infer candidate genes that explain pheno-
typic variety, and hence, enable the formulation of evolution-
ary/devolutionary hypotheses.
Processing of phenotypes: summary
The quality and range of phenotype applications are curbed
only by the quality and availability of the underlying data.
Limitations arise, for example, from the missing or incorrect
cross-species phenotypes alignment, either owing to their foun-
dational representation or owing to inconsistencies in the level
of granularity. Similarly, challenges are encountered when rep-
resenting and acquiring the more profound dimensions of
phenotypes, including degrees of severity, use of ambiguous ex-
pressions or temporality (in a longitudinal data sense), which
then hamper the development of complex solutions.
A future perspective of phenome research
For the entire field of Phenomics to advance, challenges have to
be overcome at the universal level, as well as at the level of the
individual dimensions of phenome research (representation,
acquisition, interoperability and processing). The most import-
ant universal challenge is the lack of a shared understanding of
what a phenotype is among all scientists working with pheno-
type data. This includes (computational) biologists, regardless
of the research questions and/or animal model they are working
826 | Oellrich et al.
on, as well as clinicians working in all different areas of human
medicine. To reach a common understanding, reporting stand-
ards and guidelines need to be derived that facilitate communi-
cation across domains as well as large-scale computational
analysis.
Furthermore, universal agreement has to be found as to
what additional aspects of phenotypes are relevant and have
not or only sparsely been accounted for in any of the four do-
mains. Such aspects include types of measurements, proven-
ance, evidence and time. To overcome the social barriers to
adoption, some sort of credit assignment mechanism, akin to
citation, will be necessary to track the usage of ‘good’ and reus-
able phenotypes. Existing author tracking systems such as
ORCID (http://orcid.org/) and ResearcherID (http://www.
researcherid.com/) can probably be reused to document author-
ship of phenotype models, and track usage as well as
provenance.
Another important universal issue to overcome is the re-
cording of ‘normal’ phenotypes. Currently, phenomics in the
area of disease gene discovery is geared toward the collection
and analyses of ‘abnormal’ phenotypes, e.g. those resulting
from diseases or gene modifications. However, the derivation of
an ‘abnormal’ phenotype is always the result of a comparison
with what is considered to be ‘normal’, which is collected only
in some cases [45]. The record of more ‘normal’ phenotypes
would allow for more fine-grained analyses and the investiga-
tion of causal relationships between different conditions, e.g. in
cases of comorbidity.
From a representational point of view, the ultimate future
goal is to overcome the limitations of species- and domain-
specific representations and find a universal way of encoding
phenotype data, independent from the granularity of the data.
In addition, resources need to be built that address so far miss-
ing aspects such as evidence or time aspects. For example, a
small set of evidence codes have been established as part of GO
to provide provenance in gene annotations, but also to provide
means for computational analysis to avoid data circularity.
Another aspect of phenotypes that has not been integrated yet
into the representation of phenotypes are causality and tempor-
ality, for example how the phenotypes change over time owing
to stimuli in the environment or medication. While at the mo-
ment the representations focus on reporting either a temporary
snapshot of an individual examined in an experiment or as part
of a medical investigation, the current representation models
do not allow for the encoding of phenotype changes over time
as a result to surrounding stimuli.
As we extend the scope of our joint understanding of pheno-
types and adopt ways to represent this understanding, the ac-
quisition of phenotypes has to change, too. Methods have to be
developed that can accommodate the recording of additional
aspects, such as evidence and time, e.g. when extracting infor-
mation from the scientific literature. Furthermore, more reliable
automated methods are needed that can cope with the com-
plexity of free text in clinical settings as well as reporting mech-
anisms in wet lab environments, to facilitate high-throughput
and overcome the need for time- and cost-intensive manual
labor. In addition and as mentioned earlier, the acquisition di-
mension should also address the collection of ‘normal’ pheno-
types in the future to improve the results obtained by
processing the phenotype data.
Despite the widespread aims to achieve interoperability and
make best use of the integrated resources, there are still chal-
lenges that need to be addressed to achieve true interoperability
of the existing and newly emerging resources, both phenotype-
specific and not. A long-term goal of the dimension of inter-
operability is direct propagation of experimental findings into
prevention and treatment options for patients in a hospital
(‘from bench to bedside’). Related to this goal is the aim of per-
sonalized treatments, by means of building patient-specific
models, integrating phenotype data, that can then be used for
simulations of possible treatment outcomes.
In the future, we anticipate a migration toward describing
phenotypes as ‘models’ or classifiers that answer a particular
question. For example ‘does the patient have pneumonia?’ or
‘does the patient have sepsis?’. The use of phenotyping will
then be analogous to the use of classifiers in spam filters; al-
ways running in the background and when an incoming sample
(a patient record for example) results in a high confidence
match, we would automatically receive an alert that the patient
is potentially eligible for a clinical trial, is likely to benefit from a
certain therapy or is at increased risk for certain complications.
With the improvement in any of the other dimensions, the
processing of phenotypes will improve owing to an increase in
the quality of data, but at the same time, will require extensions
that can cope with additional data available in the future, such
as ‘normal’ phenotypes, evidence for phenotype data and
causal relationships encoded with time-dependencies. In gen-
eral, a wide range of support and analysis tools are required to
unlock the full potential of phenotype data.
Given the achievements in the past years, we look forward
toward an exciting and promising decade of phenomics, with
ample opportunities for researchers to get involved and contrib-
ute to evolve and shape the emerging landscape.
Key Points
• Over the course of the past decade, phenotype data
has become a key factor in analyzing diseases and re-
porting experimental outcomes.
• Successful applications of phenotypes include the de-
scription of experimental outcomes (e.g. the changes in
phenotypes owing to gene modifications), computational
knowledge discovery (e.g. in determining disease gene
candidates) and reporting in clinical environments (e.g.
patient monitoring).
• The research field of phenomics can be divided into
four main dimensions (presentation, acquisition, inter-
operability and processing), each of which is depend-
ent, to some extent, on the others.
• While the development of each of the four dimensions
is individual, a common understanding and universal
guidelines need to be established on how phenotypes
are perceived and how they are used; a synchroniza-
tion of efforts is needed.
• The future of phenomics research holds exciting chal-
lenges and has the potential to create a significant im-
pact on the entire biomedical domain.
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